Diabetes Trials Unit
The Diabetes Trials Unit (DTU) is a clinical trials unit specialising in performing local, national and multinational clinical trials related to treating and managing diabetes and other cardiometabolic and related conditions. We work collaboratively with researchers and organisations to support trials and other studies.
Director
-
Amanda Adler
Professor of Diabetic Medicine and Health Policy
What's new
TriMaster patient preference study results presented at the IDF
13 December 2022
Trial to test diabetes drug for reducing risk for Alzheimer's Disease
22 September 2022
Latest publications
-
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation
-
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Journal article
Bethel MA. et al, (2023), Cardiovasc Diabetol, 22
-
Association of osteocalcin, osteoprotegerin and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
Journal article
Maddaloni E. et al, (2023), Diabetes Metab Res Rev
-
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Journal article
Othonos N. et al, (2023), Nat Commun, 14
-
Teplizumab approval for type 1 diabetes in the USA.
Journal article
Beran D. et al, (2023), Lancet Diabetes Endocrinol, 11, 78 - 80
|
